PDF Archive

Easily share your PDF documents with your contacts, on the Web and Social Networks.

Share a file Manage my documents Convert Recover PDF Search Help Contact

20191206 2 international symposium uro oncology uniklinik koeln разблокирован .pdf

Original filename: 20191206-2-international-symposium-uro-oncology-uniklinik-koeln-разблокирован.pdf
Title: 2nd International Symposium on Uro-Oncology
Author: Department of Urology, Uro-Oncology and robot assisted surgery, Uniklinik Köln

This PDF 1.6 document has been generated by Adobe InDesign CC 13.1 (Macintosh) / 3-Heights(TM) PDF Security Shell (http://www.pdf-tools.com), and has been sent on pdf-archive.com on 22/11/2019 at 10:19, from IP address 92.253.x.x. The current document download page has been viewed 33 times.
File size: 282 KB (5 pages).
Privacy: public file

Download original PDF file

Document preview

2nd International Symposium
on Uro-Oncology
Innovations and Controversies
in Prostate Cancer

06.-07. 2019

Dear Colleagues,
it is my pleasure to inviting you to the 2nd International
Symposium on Uro-Oncology to be held in Cologne,
Germany on December 6 and 7, 2019.
This year’s meeting will focus on innovations and constroversies in the diagnostic and theraeutic approach of
prostate cancer. State-of-the-Art presentations, pro and
contra debated as well as moderated case discussions
will make a lively interactive symposium possible.
Numerous internationally well known and clinically
highly experienced speakers from Europe and United
States accepted our invitations and will discuss with
you the hottest news in prostate cancer management.
The language of the meeting will be German and
­English with simultaneous translations, so that no
­communication boudaries should hinder interactive
Please mark the date already in your calendar and
­register early to reserving one of the limited spaces
I am looking forward to meeting you in Cologne and I
remain with best regards

Friday, December 6, 2019
13:00 Welcome
A. Heidenreich, Cologne
P. Albers, Düsseldorf

»» Prevention, early detection, diagnosis
Moderation: P. Albers, D. Pfister

13:05 E
vidence-based recommendations for
early detection
P. Albers, Düsseldorf

»» mpMRI under scrutiny

Moderation: P. Albers, D. Pfister

13:30 M
R-fusion biopsy better than TRUS-guided
B. Hadaschik, Essen
Prevention of overdiagnosis – who needs a
­mpMRI and a MR fusion biopsy
LH. Klotz, Toronto
PI-RADS3 – do we need targeted &
systematic biopsies?
J. Futterer, Nijmegen
14:15 Discussion and Case Presentations
14:35 Coffee Break

»» Organ confined prostate cancer –
­therapeutic options

Moderation: M. Ritter, M. Brausi

Univ.-Prof. Dr. Dr. h. c. Axel Heidenreich
Director and Chairman, Department of Urology

15:05 Active Surveillance is treatment of choice
M. Schostak, Magdeburg
15:15 Radical prostatectomy is treatment of choice
H.G. van de Poel, Amsterdam
15:25 LDR/stereotactic radiation therapy is
treatment of choice
Th. Wiegel, Ulm
15:35 Focal therapy is treatment of choice
LH. Klotz, Toronto
15:45 Can the pathologist help us?
R. Büttner, Cologne
16:00 Discussion and Case Presentations
16:30 Coffee Break

Friday, December 6, 2019

Saturday, December 7, 2019

»»Locally advanced prostate cancer

»» Relapse following local therapy and

Moderation: M. Matveev, C. Bach

17:00 W
hat is the most appropriate imaging study for
local and systemic staging
B. Tombal, Brussels
17:15 Pathohistology – which findings have
to be considered?
G. Kristiansen, Bonn
17:30 IMRT+IGRT, Hypofractionation, Cyberknife,
HDR-Brachytherapy – what is the standard
A. Bossi, Paris
17:50 Multimodal Therapy with neoadjuvant ARI +
­radical prostatectomy – a new standard?
R. Karnes, Rochester
18:10 Debate and Case Discussion
18:30 End of Day 1

­metastatic hormone naive prostate cancer
Moderation: S. Polyakov, R. Karnes

09:00 PSA-persistence and early biochemical relapse
following local therapy with curative intent –
­diagnostic and therapeutic approach
M. Brausi, Modena
09:20 Oligometastatic relapse – who benefits
from local salvage therapy?
R. Karnes, Rochester
09:40 Optimal systemic therapy for hmPCA –
decision support for daily rotine
N. Clarke, Manchester
10:00 Role of local therapy in hmPCA –
surgery or radiation therapy?
S. Shariat, Vienna
10:20 Discussion and Case Presentations
10:50 Coffee Break

»» Castration resistant prostate cancer
Moderation: A. Heidenreich, C. Pallasch

11:20 nmCRPC – what is new in 2019?
N. Clarke, Manchester
11:40 mCRPC – which ist he optimal sequence
A. Lorch, Zurich
12:00 Personalized diagnostics with CTCs,
­Tumor-DNA, tumor biopsy:
benefit and pitfals for daily routine
J. Schalken, Nijmegen
12:20 Innovative therapeutic options in mCRPC –
glimpse in the future
S. Chowdhury, London
12:40 Symptomatic mCRPC: options of local therapy
A. Heidenreich, Cologne
13:00 Debate and Case Discussion

»» Late Breaking new developments in

­kidney and bladder cancer from 2019

13:30 D. Pfister, Cologne
14:00 End of 2nd Int. Uro-Oncology Symposium





Prof. Dr. med. Peter Albers, Düsseldorf (D)
Prof. (PhD) Alberto Bossi, Paris (F)
Prof. Dr. med. Mauricio Brausi, Modena (ITA)
Prof. Dr. med. Reinhard R. Büttner, Cologne (D)
Prof. Simon Chowdhury, London (GB)
Prof. Dr. med. Noel Clarke, Manchester (GB)
Dr. med. (PhD) Jurgen Futterer, Nijmegen (NL)
Prof. Dr. med. Boris Hadaschik, Essen (D)
Prof Dr. med. Axel Heidenreich, Cologne (D)
Prof. Jeff R. Karnes, Rochester (USA)
Prof. Laurence H. Klotz, Toronto (CAN)
Prof. Dr. med. Glen Kristiansen, Bonn (D)
Prof. Dr. med. Anja Lorch, Zurich (CH)
Prof. Dr. David Pfister, Cologne (D)
Prof. Jack Schalken, Nijmegen (NL)
Prof. Dr. med. Martin Schostak, Magdeburg (D)
Prof. Dr. med. Shahrokh Shariat, Vienna (A)
Prof. Bertrand Tombal, Brussels (B)
Prof. Henk G. van de Poel, Amsterdam (NL)
Prof. Dr. med. Thomas Wiegel, Ulm (D)

Faculty member
›› Prof. Dr. med. Mauricio Brausi, Modena (ITA)
›› Prof. Dr. med. Vsevolod Matveev, Moskau (RUS)
›› Prof. Dr. med. Sergey Polyakov (BLR)

Amgen GmbH (3000 €)
Apogepha Arzneimittel (3000 €)
Astellas Pharma GmbH (5000 €)
AstraZeneca GmbH (2000 €)
Bayer Vital GmbH (1200 €)
Bristol-Meyers-Sqibb GmbH & Co KG (1500 €)
EUSA Pharma GmbH (1000 €)
Ipsen Pharma GmbH (3000 €)
Janssen-Cilag AG (5000 €)
MDX Health BV (3000 €)
medac GmbH (1500 €)
MedTronic GmbH (1000 €)
MSD Sharpe & Dohme GmbH (3000 €)
MucoCell GmbH (5000 €)
Pfizer Pharma GmbH (1500 €)
Roche Pharma AG (1500 €)
Sanofi Aventis Deutschland GmbH (4500 €)
Takeda Pharma Vertrieb GmbH & Co KG (2000 €)

Currently, the total amount of money sponsored by
pharmaceutical companies is 47.700 €. The money will
be spent for honoraria and travel costs of the speakers,
lease cost for the auditorium, technical equipment and
hosting of the participants. All presentations and contents of the symposium are neutral without influences of
companies and medical products. Conflicts of interests
will be disclosed.

Department of Urology,
Uro-Oncology and robot assisted surgery

Dr. Heike Diekmann
Congress Communication Consulting
E-Mail: info@heikediekmann.de
Telefon: +49 (0) 221 801499-0
Registration Fees
Urologist, Oncologist, Radiation Oncologist

100,- €
50,- €

Gesellschaft zur Förderung der Forschung der
­Urologischen Universitätsklinik Köln e.V.
Kerpener Str. 62, 50937 Köln

»»Congress Venue
Radisson blu Hotel
Messe-Kreisel 3, 50679 Köln
Phone: +49 (0) 221 277200
We have blocked rooms for the symposium

The Center for Integrated Oncology (CIO) is the joint cancer center
of the University Hospitals Aachen, Bonn, Cologne and Duesseldorf.

Related documents

prostate cancer therapeutics market
310812900 final announcement roicam 4
9783662490105 c1
natural hormone therapy palm springs
antibody drug1
darrel e drachenberg cv dedd updated aug 2013 most recent

Related keywords